Dr. Michelle A. Van Name
Pediatric Endocrinology (Pediatric Endocrinology Physician)
At a glance
- In the NPI registry since
- 2008
Licensed in Connecticut since 2011, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Endocrinology Physician primary
CT license 50005 (first issued 2011; active in renewal)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $1,324 in total to this clinician.
| Mannkind Corporation | $1,275 |
|---|---|
| Abbott Laboratories | $48.67 |
| Compensation for services other than consulting (speaking, faculty) | $1,275 |
|---|---|
| Food and Beverage | $48.67 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Mannkind Corporation Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty) AFREZZA · DIABETES MEDICINE | $1,275 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $148,723 in research payments for these studies, mostly to the institutions running them.
- ISS-001493
Novo Nordisk Inc - A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Sanofi US Services Inc. · Recruiting · NCT07088068 - A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Eli Lilly and Company · Recruiting · NCT06739122
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.